<DOC>
	<DOCNO>NCT02068053</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( PK ) , metabolism , rout extent elimination , well safety tolerability single oral solution dose [ 14C ] Bristol-Myers Squibb ( BMS ) -986020 healthy male subject .</brief_summary>
	<brief_title>Absorption , Distribution , Metabolism Excretion ( ADME ) Study BMS-986020</brief_title>
	<detailed_description>Primary purpose : Other - This study investigate pharmacokinetic , biotransformation , rout elimination , mass balance BMS-986020 human . The knowledge rout elimination drug metabolite useful evaluate likelihood effect renal hepatic impairment disposition BMS-986020</detailed_description>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy male subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body weight least 50 kg ( 110 lb ) , Body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive . Body mass index = weight ( kg ) / [ height ( ) ] 2 Men , age 18 50 year , inclusive Men sexually active woman childbearing potential ( WOCBP ) ( except vasectomy document azoospermia 90 day procedure ) must agree follow instruction method ( ) contraception duration treatment plus 5 halflives investigational drug ( 4 day ) plus 90 day ( duration sperm turnover ) total 94 day posttreatment completion Any significant acute chronic medical illness Current recent ( within 3 month study drug administration ) gastrointestinal disease Current recent history constipation irregular bowel movement ( less per 2 day ) Any major surgery within 4 week study drug administration Any gastrointestinal surgery could impact upon absorption study drug , include cholecystectomy History Gilbert 's Syndrome Donation blood plasma blood bank clinical study ( except screen visit ) within 4 week study drug administration ( within 2 week plasma ) Blood transfusion within 4 week study drug administration Inability tolerate oral medication Inability venipunctured and/or tolerate venous access Recent ( within 6 month study drug administration ) history smoke Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECGs , clinical laboratory determination beyond consistent target population History allergy LPA1 antagonists related compound</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>